

INDEX*

A

- Accessory sex organs 150
- Acid phosphatase 9, 17-19, 29, 31, 45-47, 52, 79, 98-107, 125, 127, 131
 - plasma levels 9
 - prostatic 131
 - secretion 50f, 102, 106
 - serum levels 9, 29, 79, 131
- Acini 6, 23, 116-118f, 148
 - irregular secretory 7
 - isolated 156
 - prostatic 46, 54
- Acute inflammatory changes 14
- Acute prostatitis 20t
- Adenocarcinomas 19, 62, 116-117, 145
 - grading of 116-117
 - of prostate grade 54f
 - prostatic 116-117
 - prostatoductal 25
- Adenosine triphosphate 84
- A₂ diffuse microcarcinoma 44
- Adrenal androgens 17
- Adrenal cortex 61
- Age of tumor 63
- Age-related changes 21
- Albarran's subcervical glands 6f
- Alcian blue staining technique 55
- Aldolase syntheses 101
- Alkaline 127
- Alkaline phosphatase (ALP) 51, 83
- Aliphatic polyamines 17
- Alveoli 14, 167-170
- Aminopeptidases 47, 50-53
- Amylase 9, 83
- Anaplasia (anaplastic) 168
 - alterations 166
 - cancer 44
- Androgens (androgenic) 10, 15, 17, 23, 32, 59, 61, 90, 98, 107
 - action
 - biochemical markers for 99, 100
 - mechanism of 98
 - binding of 162
 - binding protein
 - molecular weight 163
 - in circulating blood 160
 - control
 - of the prostate 102
 - of the ventral prostate 98-107
 - deprivation 15, 62
 - estrogen ratio 26
 - levels 91
 - metabolism 99f, 162
 - nuclear 26
 - in the prostate 163
 - pool estrogen 26
 - in prostatic tissues 160
 - uptake of 162
 - receptors 10, 61, 88-91, 164
 - regulation
 - in the prostate of Rhesus monkey 160-164
 - serum 161
 - stimulation 163
 - synthetic 163
- Andrology 11
- Androstenediols 23
- 5 α -androstane 3 α , 17 β -diol 99
- 3 α -androstane diol 102
- 3 β -androstane diol 105, 107
- Androstenedione 15, 161, 163
- Aneuploid cell lines
 - treatment of 170
- Animal models 33
- Anti-androgens 10
 - agents 166
 - atrophy 10
 - therapy 64
- Antibody requirements 133
- Antigen 31
 - requirements 133
- Antimicrobials 113
- Apex 13
- Apical plasmalemma 7
- Arterial blood supply 6
- Ascending urethral infection 23
- Aspiration biopsy 109

B

- Basal cells 7, 9
- Basal lamina 9
- Benign 115
 - hypertrophy 6
 - nodular hyperplasia 7, 20
- Benign proliferative lesions 19
 - prostatic hypertrophy (BPH) 23, 30, 72
- Benzo treatment 170
- Beta-glucuronidase 51
- Beta-glycerophosphate 125
- Binding proteins 90-93

* f = figure; t = table

- Biochemical techniques 29
 Biopsy (of the prostate) 110
 perineal 109, 110
 retropubic (open) 110
 Biosynthesis (polyamine) 101
 Bladder 6
 Blood groups 86
 Blood markers 79
 Bodansky method 125
 Bone alkaline phosphatase isoenzyme value 83
 Bone marrow 124-125
 acid phosphatase 31, 124-129
 markers in 88
 Bone metastases 65
 Bone scanning 125
 Bound estradiol 92
 2-bromo- α -ergocryptine 102
 Bulbous urethra 15
- C**
 Calcium 127
 Cancer of the prostate
 see prostatic carcinoma
 Carcinoembryonic antigen (CEA) 85
 Carcinogenesis 154
 mechanism of 145-146
 Carcinogens 146, 166-173
 effect of 166-173
 environmental 146
 induced 170
 potential of chemicals 166
 on prostatic explants 166-173
 treatment 170
 Carcinoma 6, 38
 metastatic 9, 47
 occult 30
 prostaglandular 20t
 Carcinomatous lesions 27
 Carcinomatous prostates 10
 Carcinosarcoma 62
 Cardiovascular complications 60
 Castration 10, 15, 18, 23
 of animals 62
 of rodents 11
 Caudal lobes 162
 Caudal prostate 162
 Cell
 culture systems 166
 kinetic studies 62
 models (malignant) 157
 multiplication 154
 proliferation (stimulation) 168
 renewal 10
 Central zones 6
 Chemical agents 166
 Chemical carcinogens
 application of 62
 Chemotherapeutic agents 166
 Chemotherapy 33, 158
 summary of 180
 Chromatin
 nuclear 32
 Chromatography 162
 Chronic debilitating disease 21
 Chronic granulomatous prostatitis 20t
 Chronic inflammatory changes 14
 Chronic nongranulomatous prostatitis 20t
 Citrate 101, 106
 acid 9
 Clinical carcinoma 30
 detection 27f
 examination 27
 markers 79-93
 response 62
 staging 28
 Cloaca 5
 Coagulase 18
 Colcemid metaphase arrest technique 168
 Collagen
 physiological breakdown 147
 Collagenase 147, 148
 Colon
 cancer of 86
 Congenital cysts of the prostate 14, 15
 Connective tissue
 capsule 9
 invaded by cancer cells 53
 stroma 53
 Corpora amylacea 9-11, 14, 16f, 23
 Corpora calculi 14, 16f
 Corticosteroids
 treatment with 85
 Counterimmunoelectrophoresis (CIEP) 80, 81, 128, 132
 Cowper's gland
 duct of 15f
 Cranial prostate 162
 Creatine kinase 84
 Creatine phosphokinase 84
 Cribriform prostatic carcinoma 54
 Cyproterone acetate
 administration of 85
 Cytochemical localization of prostatic acid 155
 Cytology (cytologic)
 diagnosis of prostatic secretions 40
 examination 109
 grading 110
 regressions 41
 studies 38
 Cytopathology 29
 Cytoplasm 167
 androgen receptor 26
 changes 38
 supranuclear 7, 168
 Cytosol 61
 Cytosolic androgen receptors 98
- D**
 DaFano's silver impregnation method 52
 Debilitating disease 19
 Dehydroepiandrosterone 161
 Dehydrogenase 127
 Development of the prostate 5
 Diagnostic procedures 26-27
 Diethylstilbestrol 92
 Differentiation of prostate carcinoma 19
 Diffuse atrophy 19
 Dihydrotestosterone 161-162
 5 α -dihydrotestosterone (5 α DHT) 32, 98-102, 105, 155-156, 162
 effects of 154
 Dilated prostatic ducts 16f

- Diseased prostatic tissues 90
DNA content 10
 degradation in spermatozoa 9
 synthesis 98
Dog
 approaches to drug therapy 33
Drug therapy
 approaches 32-34
Duct of Cowper's gland 15f
Ducts 7
Ductus deferens 5-6
- E**
Ejaculate 9
Ejaculatory ducts 5, 6f, 13, 15f
Embryology 5
 embryological lobes 5
 embryologic origins 5f
Endocrine aspects 59-65
 imbalance 23
 parameters 15-17
 profile 32
 summary of 176
 therapy 59-65, 92
Endogenous steroids 89
Endoplasmic reticulum (RER) 7, 168
Environmental carcinogens 146
Enzymes
 markers 79
 oxidative 51
 profile 44
 proteolytic 9, 51
 respiratory 15
Enzymology
 summary of 176
Eosinophilic large nucleoli 29
Epidermal growth factor 156
Epithelium 5, 7, 11, 116-118, 170
 atrophic 118f
 atrophy 23
 of carcinogen-treated explants 168
 cells 14, 146, 148, 166
 growth 148
 cuboidal 116
 cylindrical 116
 isolation of 147
 lesions (malignant) 166
 prostatic (human) 147, 149, 151, 153-154
 post-pubertal 148
 pseudostratified 7
Esterases 51
Estradiol 62
Estrogens 10, 59, 60, 102, 119-120
 administration of 63
 binding component 164
 receptors 92
 stimulation 63
 therapy 32, 166
 treatment 33, 60, 64, 85, 119-120
Excretory ducts 7
Experimental animals 62
- F**
Fibrinolysin 18
Fibroadenoma 62
Fibroblasts 153, 166
Field experiment 73
 Franzen-needle 38
FSH 33
Functional Anatomy
 of the prostate 5-11, 13-34
Functional biochemistry 17
- G**
Geographical differences 13
Gestonorone 60
Giant nuclei 41
Glandular prostate 23
 -glucuronidase 89
Gland weight 10
Glycolytic activity 15
Glycosaminoglycans (muco-polysaccharide) 55
Glycosidases 51
Golgi apparatus 52
Golgi complex 153
Golgi cisternae 45
Golgi region associated enzymes 52
Gonadotropin
 inhibition of 102
Granulomatous prostatitis
 chronic 20t
Gross anatomy 6-7
- H**
Hematogenous infection 23
Heparan sulfate (HS) 56
Histochemistry 44-56
 methodology 50
 of prostatic acid phosphatase 45
Histology (histological) 7-9
 carcinoma 146
 changes 115
 classification 20
Histopathology 29
Histophysiology 9-11
Hormone
 levels
 seasonal rhythm of 160
 manipulation 61, 63
 markers 84
 receptors 17, 31
 steroid-peptid 19
 therapy 32, 38, 155
 clinical 65
 treatment 63
17 α -hydroxyprogesterone 15
 serum levels 32
Hypercholesterolemia 87
Hyperchromatism (nuclear) 29, 40f
Hyperplasia 10, 63, 168, 170
 alterations 166
 changes 168
 lesions 170
 lobular 30
 postsclerotic 31
Hyperproliferation 168, 170
Hyperprolactinemia 17
Hypertrophy 10
 benign 6, 23, 30, 72
 prostatic gland 119f

Hypervitaminosis 153
 Hypogastric plexus
 inferior 7

I

Immuno-histochemistry 51
 Immunodiffusion 128
 Immunology
 summary of 176
 Incidental ages of prostatic cancer 72
 Incidental carcinoma 30
 Inferior hypogastric plexus 7
 Infertility (male) 14
 Inflammatory cells
 mononuclear 23
 Inflammatory changes
 acute 14
 Innervation 7, 9
 Insulin 152, 153, 156
 effects of 150
 Interstitial cells 61
 Interstitial stroma 63
 In vitro models 145-158
 Isoenzymes 45
 lysosomal 102
 Isolated acini 156
 Isolation of normal prostatic epithelium 147

K

Keratinization 153

L

Lactic dehydrogenase 127
 Leydig cells 26
 LH 33
 Lobation pattern 6
 Lobular hyperplasia 30
 Lumen 10, 45
 Lymph 6, 126
 Lymphadenectomy (pelvic) 126
 Lysosomal isoenzyme 102
 Lysozyme 9

M

Male infertility 14
 Malignant 115
 cell models 155, 157
 epithelial lesions 166
 prostate 19
 Marital status 13
 Marrow 124-125
 Mass screening
 experiments 74t
 programs 73
 for prostatic diseases 72
 system 71
 Mesenchyme 5
 Mesonephric ducts 5
 Metaplasia 5
 Metaplastic squamous epithelium 42f
 Metastatic carcinoma 9
 Metastatic prostatic cancers 47
 3-methylcholanthrene 168
 Methyltrienolone 163
 Mitochondria 167

Mitotic

activity 10, 154
 inhibition 10
 stimulatory (effect of) 168
 Model experiment 72
 Monkey 33
 Mononuclear inflammatory cells 23
 Mortality rate 13, 21, 60
 summary of 176
 Mucopolysaccharides 14
 Mucopolysaccharides of connective tissue 55
 Müllerian ducts 5, 20
 Müllerian inhibiting factor 5

N

Needle biopsy 109, 111
 Neoplastic prostatic cells 11
 Nervous innervation 7, 9
 Neuraminic acid 86
 Nodes 126
 Nodular prostatic hyperplasia (NPH) 20-22, 30
 Non-carcinogens
 effects of 168
 Non-hormonal treatment 65
 Nonmyelinated nerve fibers 9
 Normal cell models 145, 156
 mechanism of transformation 145
 Normal prostatic acinus 46, 54
 Normal prostatic epithelium 147, 149, 151, 153-154
 Nuclear androgen receptor 26
 Nuclear chromatin 32
 Nuclear hyperchromatism 29
 Nucleoli
 wasting of 41
 Nucleoside-diphosphatases 52

O

Objective regression (partial) 65
 Occult carcinoma 30
 Open biopsy of the prostate 110
 Open perineal biopsy 110
 Open retropubic biopsy 110
 Orchiectomy 59, 63, 64, 85, 166
 Organ culture models 166
 Ornithine decarboxylase 101
 Oxidative enzymes 51

P

Paraprostate 13
 Parenchyma 14
 Pathological prostates 91
 summary of 179
 Partial objective regression 65
 Pelvic lymphadenectomy 126
 Perineal aspiration biopsy of the prostate 109, 110
 Perineal biopsy (open) 110
 Perineal prostatectomy 110
 Perineural invasion 29
 Peripheral zone 6, 7
 Periurethral gland mass 13
 Phosphatase 124-125
 Physiomorphology (regional) 13-34
 Physiopathology
 of human prostate 13-34
 mechanisms 23

- of prostatic diseases 19
- quantitative 13-34
- summary of 179
- Pituitary 61
- Placental proteins 86
- Plasma level
 - seasonal rhythm 161
 - testosterone 161
- Plasminogen activator 9
- Polyamines 86, 87, 101
- Postsclerotic hyperplasia 31
- Premalignant epithelial lesions 166
- Preneoplasia 168
- Preneoplastic hyperplasia 154
- Primitive urethra 5f
- Principal cells 7
- Production Rate
 - in man 161
 - in monkey 161
- Progesterone 15, 60
 - receptors 93
- Progestin
 - cytosolic receptors 91
 - receptors 91
- Prolactin 11, 15, 17, 33, 85, 98, 102
- Prophylactics 166
 - effects of 170
- Prostaglandins 17, 18
- Prostaglandular carcinoma 20t
- Prostate (prostatic)
 - acid phosphatase 29, 65, 88, 131-138, 156
 - cytochemical localization of 155
 - immunoassay values 136
 - immunological assay 132
 - isoenzymes 82
 - in non-prostatic disorders 139
 - acini 29, 46, 54, 147, 148f
 - adenocarcinoma 33, 54
 - in baboon 163-164
 - biochemical markers (hormonal control) 98-107
 - biopsy 109-113, 115-122
 - calculi (exogenous) 14
 - carcinoma 137, 176
 - clinical detection of 27f
 - cribriform 54
 - cytologic grades 41
 - differentiation of 19
 - estrogen (treatment) 121f
 - etiology of 145
 - follow-up of 38-43
 - grading of 116-117
 - incidence of 145
 - incidental age of 146
 - staging of 45
 - summary of (classification, complications, diagnosis, grading, etiology, immunology, enzymology, metabolism, mortality, occurrence, pathology, structure) 178-179
 - therapy of 166
 - treatment of 92, 155
 - ultrasonotomogram 76, 77f
 - cells 90
 - neoplastic 11
 - concretions 14
 - cysts 14
 - cytology 38-43
 - development of 5
 - diseases 71, 115-122
 - mass screening of 71-78
 - physiopathology of 19
 - ducts 23
 - dilated 16f
 - epithelium 18, 146-147, 151, 153, 154, 168
 - cells 10f, 50, 149
 - characterization 155
 - growth of 151
 - hyperplasia 19
 - isolation of 147
 - post-pubertal 148
 - explants 168-170
 - morphology of 167
 - system 168
 - treatment of 166
 - fluid 9, 18, 19, 88
 - markers in 87
 - gland 10, 45, 51-53, 60, 61, 98, 166
 - changes of 42f
 - epithelium 138
 - hypertrophied 116, 119f
 - mass 13f
 - preoperative 116
 - of the rhesus monkey 160
 - growth 61
 - histology 116-117
 - hormonal control 98-107
 - hormone treated 38
 - hyperplasia 26
 - hypertrophy (benign) 115
 - lobe zones 15
 - malignant 19
 - massage 28, 79
 - mouse 167
 - needle biopsies 92
 - neoplasm (summary of) 179
 - open biopsy of 110
 - organ culture 167-168
 - pathologically normal 91
 - physiopathology of 13-34
 - proper 7
 - secretions 9, 10, 17, 19
 - cytologic diagnosis of 40
 - squamous metaplasia 20
 - stroma 93
 - tissue 90
 - diseased 90
 - markers in 88
 - utricle 5
 - weight 100
 - Prostatectomies 148
 - perineal 110
 - Prostatitis 20, 23, 72
 - acute 20t
 - Prostatoductal
 - adenocarcinoma 25
 - adenomatoid hyperplasia 30
 - carcinoma 20t
 - fibroadenoid hyperplasia 30
 - hyperplasia 30
 - papillary hyperplasia 30
 - planophytic hyperplasia 30
 - regenerative atypia 30

- Prostatoglandular carcinoma 13, 23, 24, 28
 staging of 28
- Protein hormone action 17
- Proteolytic enzymes 9, 51
- Pseudostratified epithelium 7
- Puberty 6
- Puboprostatic ligaments 6
- Q**
- Quantitative physiopathology 13-34
- R**
- Racial differences 13
- Radial immunodiffusion 128
- Radiation therapy 41, 166
- Radioactivity 162
- Radioimmunoassay (RIA) 80, 128, 131-138
- Radiotherapy 38, 120-122
 following biopsy 121-122
 summary of 180
- Rat 34
 prostate 98
 steroid mechanism of 99f
- Rectal examination 6, 2f
- Rectal palpation (of the prostate) 75
- Rectovesical septum 6
- 5 α -reductase 88, 89, 162
- Refractory cells 170
- Regan isoenzyme 82
- Regional physiopathology 13-34
- Regressive stage 40f
- Remission 65
- Respiratory enzymes 15
- Resting fluid 19
- Retinoids 166f, 170
 acid 171
 comparative activity of 171
 effects of 166
 on prostatic explants 166
 toxic effects of 171
- Ribosomes 167
- Roentgenologic examinations 27
- Roy method 129
- S**
- Scanning (bone) 125
- Sclerotic atrophy 19
- Secondary male sex traits 17
- Secondary (postatrophic hyperplasia) 30
- Secretions (secretory)
 acid phosphatase 102, 106
 cells 45, 167
 epithelial cells 153
 isoenzymes 102
 of the prostate 6, 9, 10, 17
 prostatic acinus 53
- Seminal
 coagulum 9
 fluid 19
 plasma (prostatic contribution) 19
 semin 9
 vesicles 5, 6f, 15, 17
- Serial biopsies
 in follow-up 120-121
 variations and significance 120-121
- Serial prostatic biopsies 120-121
 significance of changes in 121-122
- Sertoli cells 26
- Serum
 acid phosphatase 29, 79
 amylase 83
 androgens 161
 glycoproteins 86
 prolactin 85
 ribonuclease activity (RNase) 83
 selection of 149
 steroids 84
 testosterone level 161
- Sex hormone 84
- Sodium 129
- Solid phase immunofluorescence (SPIF) 80
- Spermatozoa 19, 52
- Spermidine 101
- Spermine 17, 19, 101
- Sperm metabolism 19
- Sperm motility 14
- Squamous metaplasia 153, 168
 benign 41
- Steroid contents 90
 hormone receptors data 90
 metabolism 99f
 metabolizing enzymes 100
 oxido-reductase enzymes in prostatic tissue 88
- Steroid-peptide hormone (lactogen) 19
- Steroid receptors 59-65, 92
- Stroma 7, 9, 11
 invasion 44-56
- Supranuclear cytoplasm 7
- Synthetic analogs 166
- T**
- Tartrate 80, 103, 105, 106f
- Testicles 52
- Testicular steroidogenesis 59
- Testis 23, 61
- Testosterone 10, 11, 17, 33, 60, 61, 98, 102, 150, 154, 163
 administration 101
 binding globulin 84
 biosynthesis 102
 conversion of 162
 injections 106
 plasma 160
 production 160
- Therapy 63
 effects 170
 radiation 41, 166
 summary of 180
- Thymolphthalein 126
- Toxic side effects 166
- Tracheal organ cultures 170
- Transducer tube 73f
- Transitional zone 7
- Transperineal needle biopsy 112
- Transrectal aspiration biopsy 38, 41, 109
- Transrectal needle biopsy 112
 accuracy of 112
 complications of 113
- Transrectal ultra sonotomography 71
 chair type scanner 72
- Transurethral biopsy 111

- Transurethral prostatectomy 111
- Travenol disposable biopsy
 - needle 111f
- Travenol needle 112
- Treatment of prostatic cancer 92, 155
- True prostate 7
- Tubuloacinar gland 7
- Tumor
 - age of 63
 - cells 154
 - growth 33
 - mass 65
- U**
- Ultrasonotomography
 - transrectal 71, 72
- Ultrastructure 7-9
 - differentiation 20
 - summary of 176
- Urethra 6, 7
 - infection (ascending) 23
 - primitive 5f
- Urine (urinary)
 - cholesterol levels 87
 - hydroxyproline 87
 - markers in 87
- Urogenital diaphragm 6, 15
- Urogenital sinus 5
- Urorectal septum 5
- Utricle 6
- V**
- Vacuoles
 - large empty 39
 - melting of 39
- Venous plexus 6
- Vertebral plexus 6
- Vesical orifice 13f
- Vesical plexus 7
- Vitamin A 154, 156, 166
 - deficiency 171
 - effects of 153
- W**
- Wolffian ducts 5
- Z**
- Zinc 9, 11, 17, 18, 31, 52, 53, 101, 102, 106
 - albumin 19
 - binders 93
 - in the epithelium 101
 - ions 19
 - levels 91